Laboratorios Farmaceuticos ROVI (ROVI) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.116x

Based on the latest financial reports, Laboratorios Farmaceuticos ROVI (ROVI) has a cash flow conversion efficiency ratio of 0.116x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€73.37 Million ≈ $85.78 Million USD) by net assets (€632.80 Million ≈ $739.81 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Laboratorios Farmaceuticos ROVI - Cash Flow Conversion Efficiency Trend (2006–2024)

This chart illustrates how Laboratorios Farmaceuticos ROVI's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ROVI liabilities breakdown for a breakdown of total debt and financial obligations.

Laboratorios Farmaceuticos ROVI Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Laboratorios Farmaceuticos ROVI ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Paladin Energy Ltd AU:PDN	-0.003x
Huaan Securities Co Ltd SHG:600909	0.085x
KENON HLDGS LTD F:76N	0.032x
Amneal Pharmaceuticals, Inc. Class A Common Stock NASDAQ:AMRX	21.854x
Capricorn Metals Ltd AU:CMM	0.162x
Kilroy Realty Corp NYSE:KRC	0.015x
Vontobel Holding SW:VONN	0.544x
Cosco Shipping Development Co Ltd SHG:601866	0.051x

Annual Cash Flow Conversion Efficiency for Laboratorios Farmaceuticos ROVI (2006–2024)

The table below shows the annual cash flow conversion efficiency of Laboratorios Farmaceuticos ROVI from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see ROVI stock market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€581.54 Million ≈ $679.88 Million	€138.28 Million ≈ $161.66 Million	0.238x	+14.11%
2023-12-31	€543.49 Million ≈ $635.40 Million	€113.25 Million ≈ $132.40 Million	0.208x	-54.28%
2022-12-31	€521.38 Million ≈ $609.55 Million	€237.60 Million ≈ $277.78 Million	0.456x	+43.62%
2021-12-31	€470.98 Million ≈ $550.62 Million	€149.44 Million ≈ $174.71 Million	0.317x	+152.96%
2020-12-31	€373.70 Million ≈ $436.89 Million	€46.88 Million ≈ $54.80 Million	0.125x	+547.14%
2019-12-31	€322.39 Million ≈ $376.90 Million	€-9.04 Million ≈ $-10.57 Million	-0.028x	-194.53%
2018-12-31	€287.47 Million ≈ $336.08 Million	€8.53 Million ≈ $9.97 Million	0.030x	-68.47%
2017-12-31	€191.69 Million ≈ $224.10 Million	€18.04 Million ≈ $21.09 Million	0.094x	-62.09%
2016-12-31	€183.41 Million ≈ $214.42 Million	€45.53 Million ≈ $53.22 Million	0.248x	+39.17%
2015-12-31	€164.78 Million ≈ $192.65 Million	€29.39 Million ≈ $34.36 Million	0.178x	+22.88%
2014-12-31	€158.47 Million ≈ $185.27 Million	€23.00 Million ≈ $26.89 Million	0.145x	-29.67%
2013-12-31	€144.46 Million ≈ $168.89 Million	€29.82 Million ≈ $34.86 Million	0.206x	+33.06%
2012-12-31	€126.45 Million ≈ $147.83 Million	€19.61 Million ≈ $22.93 Million	0.155x	+39.39%
2011-12-31	€113.98 Million ≈ $133.26 Million	€12.68 Million ≈ $14.83 Million	0.111x	-45.31%
2010-12-31	€104.13 Million ≈ $121.74 Million	€21.19 Million ≈ $24.77 Million	0.203x	+51.20%
2009-12-31	€71.50 Million ≈ $83.59 Million	€9.62 Million ≈ $11.25 Million	0.135x	-48.51%
2008-12-31	€48.44 Million ≈ $56.63 Million	€12.66 Million ≈ $14.80 Million	0.261x	+1079.12%
2007-12-31	€51.92 Million ≈ $60.70 Million	€1.15 Million ≈ $1.35 Million	0.022x	-92.59%
2006-12-31	€25.81 Million ≈ $30.17 Million	€7.72 Million ≈ $9.02 Million	0.299x	--

About Laboratorios Farmaceuticos ROVI

MC:ROVI Spain Drug Manufacturers - Specialty & Generic

Market Cap

$4.75 Billion

€4.06 Billion EUR

Market Cap Rank

#4275 Global

#34 in Spain

Share Price

€79.40

Change (1 day)

+0.95%

52-Week Range

€51.35 - €85.55

All Time High

€90.54